Literature DB >> 9708515

Carbon-11-methionine uptake in squamous cell head and neck cancer.

P Lindholm1, S Leskinen, M Lapela.   

Abstract

UNLABELLED: The purpose of this study was to investigate whether uptake of L-methyl-[11C]-methionine in a tumor is related to the survival of patients with squamous cell cancer of the head and neck.
METHODS: Thirty-nine patients (median age 64 yr) with newly diagnosed squamous cell carcinoma of the head and neck entered a PET study with [11C]-methionine before therapy. Tumor [11C]-methionine uptake was measured as standardized uptake values (SUVs), and the PET results were compared with the clinical follow-up data of the patients.
RESULTS: All except one of the malignant lesions within the field of view were visible by [11C]-methionine PET. The median tumor SUV was 9.0 (range 4.0-18.8). The median follow-up time for patients still alive is currently 44 mo (range 14-66 mo). No difference in survival was found between patients with tumor SUV equal to or larger than the median and those with tumor SUV smaller than the median.
CONCLUSION: Carbon-11-methionine PET imaging is effective in squamous cell head and neck cancer. The amount of [11C]-methionine uptake does not predict the clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708515

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Prognostic value of post-treatment (18)F-FDG PET/CT for advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy.

Authors:  Kimiteru Ito; Keigo Shimoji; Yoko Miyata; Kouhei Kamiya; Ryogo Minamimoto; Kazuo Kubota; Momoko Okasaki; Miyako Morooka; Jyunkichi Yokoyama
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

2.  Preclinical evaluation of an 18F-trifluoroborate methionine derivative for glioma imaging.

Authors:  Xiangyu Yang; Zhibo Liu; Huimin Zhang; Zhu Li; Jeeva P Munasinghe; Gang Niu; Gaojun Teng; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-29       Impact factor: 9.236

Review 3.  Adenoid cystic carcinoma: focus on heavy ion therapy and molecular imaging.

Authors:  Angelo Castello; Laura Olivari; Egesta Lopci
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

4.  18F-FET PET/CT in advanced head and neck squamous cell carcinoma: an intra-individual comparison with 18F-FDG PET/CT.

Authors:  Stephan Kurt Haerle; Dorothee R Fischer; Daniel T Schmid; Nader Ahmad; Gerhard F Huber; Alfred Buck
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

5.  Relationship between the uptake of 18F-borono-L-phenylalanine and L-[methyl-11C] methionine in head and neck tumors and normal organs.

Authors:  Yoshiaki Watanabe; Hiroaki Kurihara; Jun Itami; Ryohei Sasaki; Yasuaki Arai; Kazuro Sugimura
Journal:  Radiat Oncol       Date:  2017-01-14       Impact factor: 3.481

6.  Is C-11 Methionine PET an alternative to 18-F FDG-PET for identifying recurrent laryngeal cancer after radiotherapy?

Authors:  Jan Wedman; Jan Pruim; Lisa van der Putten; Otto S Hoekstra; Remco de Bree; Boukje A C van Dijk; Bernard F A M van der Laan
Journal:  Clin Otolaryngol       Date:  2018-11-18       Impact factor: 2.597

7.  [S-methyl-11C]-L-methionine positron emission tomography/computed tomography imaging parameters to evaluate early response for esophageal cancer with neoadjuvant carbon ion radiotherapy.

Authors:  Kazuo Narushima; Ryuichi Nishii; Shinichi Okazumi; Hideaki Shimada; Yasunori Akutsu; Takamasa Maeda; Shigeo Yasuda; Shigeru Yamada; Kiyohiko Shuto; Kentaro Tamura; Kana Yamazaki; Makoto Shinoto; Hitoshi Ishikawa; Mikito Mori; Hisahiro Matsubara
Journal:  Sci Rep       Date:  2022-08-11       Impact factor: 4.996

8.  Glycolysis on F-18 FDG PET/CT Is Superior to Amino Acid Metabolism on C-11 Methionine PET/CT in Identifying Advanced Renal Cell Carcinoma at Staging.

Authors:  Suk-Hyun Lee; Jee-Soo Park; Hyunjeong Kim; Dongwoo Kim; Seung-Hwan Lee; Won-Sik Ham; Woong-Kyu Han; Young-Deuk Choi; Mijin Yun
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.